Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma

Abstract excerpt

Multiple myeloma (MM) is an incurable disease characterized by clonal expansion of malignant plasma cells in the bone marrow [ 1 ]. Although the advent of novel therapeutics, including proteasome inhibitors (PIs), has greatly enhanced patient outcome, relapse is common in MM even under maintenance therapy and the period of remission decreases with each iteration of therapy [ 2 ]. The PI bortezomib (PS-341,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Multiple Myeloma Research and Treatments
• Share to Protein Degradation and Inhibitors
• Share to Ubiquitin and proteasome pathways